WE RESEARCH. WE DEVELOP. WE FIGHT.
FOR A WORLD WITHOUT TYPE 1 DIABETES.
© Helmholtz Zentrum München / Jörg Simanowski (Markenfotografie)
The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was launched in 2015 and brings together several academic research institutions and hospitals in Europe. GPPAD aims to establish an international infrastructure for studies dedicated to preventing the development of type 1 diabetes.
Read more about our studies here
We conduct studies in Belgium, Germany, the UK, Poland, and Sweden for the early detection of an increased genetic risk of type 1 diabetes and prevention of disease development.
Read more about study participation in Germany:
Increased risk of type 1 diabetes: Early detection
Freder1k: early detection for newborns up to 7 days old
New study on the prevention of type 1 diabetes autoimmunity.
SINT1A: for newborns up to 6 weeks old with an increased risk of type 1 diabetes.
Prevention study for infants with an increased risk
POInT: for infants between four and seven months old
Participation no longer possible
More than
Infants were tested for increased risk of type 1 diabetes in the Freder1k study
More than
children are taking part in our POInT prevention study